TYRA-300 Dose TBD

Phase 2

TTyra Biosciences, Inc

TYRA-300 Dose TBD is one of 2 therapeutic programs targeting NMIBC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NMIBCRecruiting

NMIBCPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in NMIBC

#DrugCompanyPhaseTrials

TYRA-300

TTyra Biosciences, Inc

Phase 2

1 2

TYRA-300 Dose TBD

TTyra Biosciences, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

NMIBC

NCT06995677

Clinical

Trials by Indication[1]

NMIBC1 trial

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Recruiting·TTyra Biosciences, Inc·Phase 2·NCT06995677·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TYRA-300 Dose TBD. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for TYRA-300 Dose TBD. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tyra Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTyra Biosciences, Inc

TYRA-300 Dose TBD

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

NMIBC1 trial

References

Drug Info

Quick Facts

Related News